Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Assets: 2014-2024

Historic Non-Current Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $3.9 million.

  • Viridian Therapeutics, Inc.\DE's Non-Current Assets rose 15.01% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 15.01%. This contributed to the annual value of $3.9 million for FY2024, which is 0.10% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Non-Current Assets stood at $3.9 million for FY2024, which was down 0.10% from $3.9 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Assets ranged from a high of $3.9 million in FY2023 and a low of $1.6 million during FY2020.
  • Its 3-year average for Non-Current Assets is $3.9 million, with a median of $3.9 million in 2024.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Assets spiked by 214.34% in 2020 and then decreased by 0.10% in 2024.
  • Viridian Therapeutics, Inc.\DE's Non-Current Assets (Yearly) stood at $1.6 million in 2020, then surged by 115.69% to $3.5 million in 2021, then climbed by 10.49% to $3.9 million in 2022, then rose by 0.71% to $3.9 million in 2023, then declined by 0.10% to $3.9 million in 2024.